ARHGEF38

Across TCGA pan-cancer cohorts, ARHGEF38 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARHGEF38 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ARHGEF38 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGEF38 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

OV, UCEC, and PRAD are the cancer types where ARHGEF38 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	III,IV	0.270	0.534	.017	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.441	.023	18	view →
PRAD	DFS	Median	All	0.085	0.774	.007	6	view →
LUSC	DFS	Median	All	1.000	0.636	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARHGEF38–OV (DFS)

Open the OV breakdown →